MS and Demyelinating Disorders

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 23, 2020.

On the heels of successful long-term data, evobrutinib seeks to maintain its high efficacy in 2 pivotal phase 3 clinical trials.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 16, 2020.

Here's what is coming soon to NeurologyLive.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 9, 2020.

The investigators noted that their results can be replicated independently in a real-world cohort, they may have clinical implications for daily practice.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending October 2, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

The free webcast programs, which will focus on cannabis use in MS and MS nursing care, will earn participants up to 3 CE credits each.

Volumetric MRI shows Hispanic patients are at a greater risk of experiencing more aggressive disease, leading to sustained disability.

The medical director manager of neuroscience at Genentech offered her perspective on the mountain of data presented at MS Virtual 2020 on the recently approved NMOSD treatment.

The study investigators noted that a higher gravidity and parity number was not associated with a delay in CIS onset.

Researchers concluded that uptitration of ponesimod was not associated with clinically significant bradyarrhythmia events; none were serious or lead to discontinuation.

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Neurology News Network for the week ending September 26, 2020.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending September 25, 2020.

In the third year of treatment, both dose cohorts did not experience any contrast-enhancing lesions, and only a small population in the Barcelona center showed new T2 lesions.

The medical director manager of neuroscience at Genentech discussed the swath of data presented on the humanized anti-CD20 monoclonal antibody at MS Virtual.

The neurology resident at NYU Langone shared her thoughts on the need for publication of clinician-based data and why maintaining a high level of mental health remains a top priority during the COVID-19 pandemic.

Early intensive treatment was more effective in controlling disability progression over time compared with an escalation therapy approach.

The director of the UCSF Weill Institute for Neuroscience spoke to the advantages of having agents that can be used across the spectrum of MS, and the role disease progression plays early on.

Patients with lower levels of disability tended to report fatigue as the most impactful symptom in daily life.

The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical detailed what makes ponesimod different from other currently FDA-approved treatments.